Publication | Closed Access

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin

Breast OncologyMedicineHypoxic CellsCancer BiologyCombination TherapyBreast CancerCell BiologyMtor PathwayOncologyRadiation OncologyTumor BiologyEndocrine-related Cancer